Pathophysiology as a basis for understanding symptom complexes and therapeutic targets

Neurogastroenterology and Motility

Volumn 16, Issue 2, 2004, Pages 135-142

  Camilleri, M ^a,b   Talley, N J ^a  

^a Clinical Enteric Neuroscience Translational and Epidemiological Research Mayo Clinic   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Biomarkers; Clinical trials; Gastrointestinal; Motility; Pharmacogenomics; Pharmacology; Sensation

Indexed keywords

ALOSETRON; AMITRIPTYLINE; BIOLOGICAL MARKER; GUANINE NUCLEOTIDE BINDING PROTEIN; LOPERAMIDE; NORTRIPTYLINE; PIBOSEROD; PRUCALOPRIDE; SEROTONIN; TEGASEROD;

CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG EFFICACY; DYSPEPSIA; GASTROINTESTINAL TRACT FUNCTION; GASTROINTESTINAL TRANSIT; HUMAN; INTESTINE MOTILITY; INTESTINE TRANSIT TIME; IRRITABLE COLON; PATHOPHYSIOLOGY; PELVIS FLOOR; PHARMACOGENOMICS; PRIORITY JOURNAL; REVIEW; SENSORIMOTOR FUNCTION; SYMPTOMATOLOGY;

ANIMALS; BIOLOGICAL MARKERS; CLINICAL TRIALS; DIGESTIVE SYSTEM DISEASES; GASTROINTESTINAL AGENTS; GASTROINTESTINAL TRANSIT; HUMANS;

EID: 2342453772     PISSN: 13501925     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2982.2004.00516.x     Document Type: Review

References (55)

1. Camilleri M. Management of the irritable bowel syndrome. Gastroenterology 2001; 120: 652-68.
2. Brandt LJ, Bjorkman D, Fennerty MB, Locke GR, Olden K, Peterson W, Quigley E, Schoenfeld P, Schuster M, Talley N. Systematic review on the management of irritable bowel syndrome in North America. Am J Gastroenterol 2002; 97: S7-26.
3. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999; 286: 487-91.
4. Moher D, Schulz KF, Altman D, the CONSORT Group The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 2001; 285: 1987-90.
5. Veldhuyzen van Zanten SJ, Talley NJ, Bytzer P, Klein KB, Whorwell PJ, Zinsmeister AR. Design of treatment trials for functional gastrointestinal disorders. Gut 1999; 45: II69-77.
6. Camilleri M. Comment from the editors: ten secrets for development of drugs for functional gastrointestinal diseases. Gastroenterology 2000; 118: 653.
7. Cann PA, Read NW, Holdsworth CD. What is the benefit of coarse wheat bran in patients with irritable bowel syndrome? Gut 1984; 25: 168-73.
8. Cann PA, Read NW, Holdsworth CD, Barends D. Role of loperamide and placebo in management of irritable bowel syndrome (IBS). Dig Dis Sci 1984; 29: 239-47.
9. Degen LP, Phillips SF. How well does stool form reflect colonic transit? Gut 1996; 39: 109-13.
10. 3 antagonist in subjects with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2001; 92: 2671-6.
11. Cremonini F, Delgado-Aros S, Camilleri M. Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized control trials. Neurogastroenterol Motil 2003; 15: 79-86.
12. Watson ME, Lacey L, Kong S, Northcutt AR, McSorley D, Hahn B, Mangel AW. Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2001; 96: 455-9.
13. Prather CM, Camilleri M, Zinsmeister AR, McKinzie S, Thomforde GM. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology 2000; 118: 463-8.
14. Müller-Lissner SA, Fumagalli I, Bardhan KD, Pace F, Pecher E, Nault B, Rüegg P. Tegaserod, a5-HT4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001; 15: 1655-6.
15. Novick J, Miner P, Krause R, Glebas K, Bliesath H, Ligozio G, Ruegg P, Lefkowitz M. A randomized, double-blind, placebo- controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Alimentary Pharmacology & Therapeutics 2002; 16(11): 1877-88.
16. Kellow J, Lee OY, Chang FY, Thongsawat S, Mazlam MZ, Yuen H, Gwee KA, Bak YT, Jones J, Wagner A. An Asia- Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Gut 2003; 52(5): 671-6.
17. 4 receptor antagonist, SB-207266, on gastrointestinal motor and sensory function in humans. Gut 2000; 47: 667-74.
18. Talley NJ. Pharmacologic therapy for the irritable bowel syndrome. Am J Gastroenterol 2003; 98: 750-8.
19. Grotz RL, Pemberton JH, Talley NJ, Rath DM, Zinsmeister AR. Discriminant value of psychological distress, symptom profiles, and segmentai colonic dysfunction in outpatients with severe idiopathic constipation. Gut 1994; 35: 798-802.
20. Lembo A, Camilleri M. Chronic constipation. New England Journal of Medicine 2003; 349(14): 1360-8.
21. Mollen RMHG, Salvioli B, Camilleri M, Burton D, Kost LJ, Phillips SF, Pemberton JH. The effects of biofeedback on rectal sensation and distal colonic motility in patients with disorders of rectal evacuation: evidence of an inhibitory rectocolonic reflex in humans? Am J Gastroenterol 1999; 94: 751-6.
22. O'Brien MD, Camilleri M, von der Ohe MR, Phillips SF, Pemberton JH, Prather CM, Wiste JA, Hanson RB. Motility and tone of the left colon in constipation: a role in clinical practice? Am J Gastroenterol 1996; 91: 2532-8.
23. Bouras EP, Camilleri M, Burton DD, Thomforde G, McKinzie S, Zinsmeister AR. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology 2001; 120: 354-60.
24. Emmanuel AV, Kamm M. Response to a behavioural treatment, biofeedback, in constipated patients is associated with improved gut transit and autonomie innervation. Gut 2001; 49: 214-9.
25. von der Ohe MR, Hanson RB, Camilleri M. Serotonergic mediation of postprandial colonic tonic and phasic responses in humans. Gut 1994; 35: 536-41.
26. von der Ohe M, Camilleri M, Kvols LK, Thomforde GM. Motor dysfunction of the small bowel and colon in patients with the carcinoid syndrome and diarrhoea. N Engl J Med 1993; 329: 1073-8.
27. 3 antagonist corrects the postprandial colonic hypertonic response in carcinoid diarrhea. Gastroenterology 1994; 106: 1184-9.
28. Hasler WL, Soudah HC, Owyang C. A somatostatin analogue inhibits afferent pathways mediating perception of rectal distention. Gastroenterology 1993; 104: 1390-7.
29. Plourde V, Lembo T, Shui Z, Parker J, Mertz H, Tache Y, Sytnik B, Mayer E. Effects of the somatostatin analogue octreotide on rectal afferent nerves in humans. Am J Physiol 1993; 265: G742-51.
30. Bradette M, Delvaux M, Staumont G, Fioramonti J, Bueno L, Frexinos J. Octreotide increases thresholds of colonic visceral perception in IBS patients without modifying muscle tone. Dig Dis Sci 1994; 39: 1171-8.
31. Hasler WL, Soudah HC, Owyang C. Somatostatin analog inhibits afferent response to rectal distention in diarrhea- predominant irritable bowel patients. J Pharmacol Exp Ther 1994; 268: 1206-11.
32. Lembo T, Naliboff BD, Matin K, Munakata J, Parker RA, Gracely RH, Mayer EA. Irritable bowel syndrome patients show altered sensitivity to exogenous opiolds. Pain 2000; 87: 137-47.
33. Riberdy-Poitras M, Verrier P, Plourde V, Boivin M, Poitras P. Amitryptilin for the treatment of IBS. Gastroenterology 2000; 118: A617.
34. Delgado-Aros S, Chial HJ, Camilleri M, Szarka LA, Weber FT, Jacob J, Ferber I, McKinzie S, Burton DD, Zinsmeister AR. Effects of a kappa opioid agonist, asimadoline, on satiation and gastrointestinal motor and sensory functions in humans. Am J Physiol 2003; 284: G558-66.
35. Stanghellini V, Tosetti C, Paternico A, Barbara G, Morselli- Labate AM, Monetti N, Marengo M, Corinaldesi R. Risk indicators of delayed gastric emptying of solids in patients with functional dyspepsia. Gastroenterology 1996; 110: 1036-42.
36. Tack J, Piessevaux H, Coulie B, Caenepeel P, Janssens J. Role of impaired gastric accommodation to a meal in functional dyspepsia. Gastroenterology 1998; 115: 1346-52.
37. Kim D-Y, Delgado-Aros S, Camilleri M, Samsom M, Murray JA, O'Connor MK, Brinkmann BH, Stephens DA, Lighvani SS, Burton DD. Noninvasive measurement of gastric accommodation in patients with idiopathic non- ulcer dyspepsia. Am J Gastroenterol 2001; 96: 3099-105.
38. Bredenoord AJ, Chial HJ, Camilleri M, Mullan BP, Murray JA: Gastric accommodation and emptying in evaluation of patients with upper gastrointestinal symptoms. Clinical Gastroenterology and Hepatology 2003; 1: 264-72.
39. Kim D-Y, Myung S-J, Camilleri M. Novel testing of human gastric motor and sensory functions: rationale, methods, and potential applications in clinical practice. A review. Am J Gastroenterol 2000; 95: 3365-73.
40. Fischler B, Tack J, De Gucht V, Shkedy ZI, Persoons P, Broekaert D, Molenberghs G, Janssens J. Heterogeneity of symptom pattern, psychosocial factors, and pathophysiological mechanisms in severe functional dyspepsia. Gastroenterology 2003; 124: 903-10.
41. Sarnelli G, Caenepeel P, Geypens B, Janssens J, Tack J. Symptoms associated with impaired gastric emptying of solids and liquids in functional dyspepsia. Am J Gastroenterol 2003; 98: 783-8.
42. Talley NJ, Verlinden M, Jones M. Can symptoms discriminate among those with delayed or normal gastric emptying in dysmotility-like dyspepsia? Am J Gastroenterol 2001; 96: 1422-8.
43. Jian R, Ducrot F, Ruskone A, Chaussade S, Rambaud JC, Modigliani R, Rain JD, Bernier JJ. Symptomatic, radionuclide and therapeutic assessment of chronic idiopathic dyspepsia. A double-blind placebo-controlled evaluation of cisapride. Dig Dis Sci 1989; 34: 657-64.
44. Boeckxstaens GE, Hirsch DP, Kuiken SD, Heisterkamp SH, Tytgat GN. The proximal stomach and postprandial symptoms in functional dyspeptics. Am J Gastroenterol 2002; 97: 40-8.
45. Talley NJ, Verlinden M, Snape W, Beker JA, Ducrotte P, Dettmer A, Brinkhoff H, Eaker E, Ohning G, Miner PB, Mathias JR, Fumagalli I, Staessen D, Mack RJ. Failure of a motilin receptor agonist (ABT-229) to relieve the symptoms of functional dyspepsia in patients with and without delayed gastric emptying: a randomized double-blind placebo- controlled trial. Aliment Pharmacol Ther 2000; 14: 1653-66.
46. Talley NJ, Verlinden M, Geenen DJ, Hogan RB, Riff D, McCallum RW, Mack RJ. Effects of a motilin receptor agonist (ABT-229) on upper gastrointestinal symptoms in type 1 diabetes mellitus: a randomised, double blind, placebo controlled trial. Gut 2001; 49: 395-401.
47. Tougas G, Chen Y, Luo D, Salter J, D'Elia T, Earnest DL. Tegaserod improves gastric emptying in patients with gastroparesis and dyspeptic symptoms. Gastroenterology 2003; 124: A54.
48. Tack J, Vos R, Janssens J, Salter J, Jauffret S, Vandeplassche G. Influence of tegaserod on proximal gastric sensory and motor function in man. Gastroenterol 2002; 122: A453.
49. Chial HJ, Camilleri C, Delgado-Aros S, Burton D, Thomforde G, Ferber I, Camilleri M. A nutrient drink test to assess maximum tolerated volume and postprandial symptoms: effects of gender, body mass index and age in health. Neurogastroenterol Mot 2002; 14: 249-53.
50. Tack J, Caenepeel P, Piessevaux H, Cuomo R, Janssens J. Assessment of meal induced gastric accommodation by a satiety drinking test in health and in severe functional dyspepsia. Gut 2003; 52: 1271-7.
51. 3 antagonism on postprandial gastric volume and symptoms in humans. Aliment Pharm Ther 2002; 16: 225-33.
52. Talley NJ, Van Zanten SV, Saez LR, Dukes G, Perschy T, Heath M, Kleoudis C, Mangel AW. A dose-ranging, placebo-controlled, randomized trial of alosetron in patients with functional dyspepsia. Aliment Pharmacol Ther 2001; 15: 525-37.
53. McLeod HL, Evans WE. Pharmacogenomics: unlocking the human genome for better drug therapy. Annu Rev Pharmacol Toxicol 2001; 41: 101-21.
54. Camilleri M, Atanasova E, Carlson PJ, Ahmad U, Kim HJ, Viramontes BE, McKinzie S, Urrutia R. Serotonin transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome. Gastroenterology 2002; 123: 425-32.
55. Holtmann G, Siffert W, Grote E, Haag S, Braun-Lang U, Langkafel M, Talley N. G-protein mediated receptor- cell-coupling as a predictor for the long term response to treatment in patients with functional dyspepsia. Gastroenterology 2003; 124: A80.